PE20201185A1 - Inhibidores de la oxacina monoacilglicerol lipasa (magl) - Google Patents
Inhibidores de la oxacina monoacilglicerol lipasa (magl)Info
- Publication number
- PE20201185A1 PE20201185A1 PE2020001119A PE2020001119A PE20201185A1 PE 20201185 A1 PE20201185 A1 PE 20201185A1 PE 2020001119 A PE2020001119 A PE 2020001119A PE 2020001119 A PE2020001119 A PE 2020001119A PE 20201185 A1 PE20201185 A1 PE 20201185A1
- Authority
- PE
- Peru
- Prior art keywords
- oxacin
- magl
- lipase
- inhibitors
- monoacilglicerol
- Prior art date
Links
- 102000004882 Lipase Human genes 0.000 title abstract 2
- 108090001060 Lipase Proteins 0.000 title abstract 2
- 239000004367 Lipase Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 235000019421 lipase Nutrition 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 PIPERIDIN-1-CARBONYL Chemical class 0.000 abstract 2
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 abstract 1
- XISPDFMAOWZEQG-UHFFFAOYSA-N 4h-1,4-oxazin-3-one Chemical compound O=C1COC=CN1 XISPDFMAOWZEQG-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- XSGHLZBESSREDT-UHFFFAOYSA-N methylenecyclopropane Chemical class C=C1CC1 XSGHLZBESSREDT-UHFFFAOYSA-N 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE OXACINA DE FORMULA (Ic) DONDE R20, R21, R22, R23, L, X, m, n Y EL ANILLO A SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: RAC-CIS-6-(4-(5-CLORO-1-(CICLOPROPILMETIL)-1H-INDOL-3-IL)PIPERIDIN-1-CARBONIL)HEXAHIDRO-2H-PIRIDO[4,3-B][1,4]OXAZIN-3(4H)-ONA; RAC-CIS-6-(4-(5-CLORO-1-METIL-1H-INDOL-3-IL)PIPERIDIN-1-CARBONIL)HEXAHIDRO-2H-PIRIDO[4,3-B][1,4]OXAZIN-3(4H)-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA MONOACILGLICEROL LIPASA (MAGL) SIENDO UTILES EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163273 | 2018-03-22 | ||
| CN2019075372 | 2019-02-18 | ||
| PCT/EP2019/057174 WO2019180185A1 (en) | 2018-03-22 | 2019-03-22 | Oxazine monoacylglycerol lipase (magl) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201185A1 true PE20201185A1 (es) | 2020-11-03 |
Family
ID=65818027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001119A PE20201185A1 (es) | 2018-03-22 | 2019-03-22 | Inhibidores de la oxacina monoacilglicerol lipasa (magl) |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210107920A1 (es) |
| EP (1) | EP3768684B1 (es) |
| JP (1) | JP7308220B2 (es) |
| KR (1) | KR20200136425A (es) |
| CN (1) | CN111936503B (es) |
| AU (1) | AU2019238381B2 (es) |
| BR (1) | BR112020014992A2 (es) |
| CA (1) | CA3089443A1 (es) |
| CL (1) | CL2020002423A1 (es) |
| CO (1) | CO2020009567A2 (es) |
| CR (1) | CR20200416A (es) |
| DK (1) | DK3768684T3 (es) |
| ES (1) | ES2942319T3 (es) |
| FI (1) | FI3768684T3 (es) |
| HR (1) | HRP20230388T1 (es) |
| HU (1) | HUE061584T2 (es) |
| IL (1) | IL276031B2 (es) |
| LT (1) | LT3768684T (es) |
| MX (1) | MX2020008894A (es) |
| PE (1) | PE20201185A1 (es) |
| PH (1) | PH12020500661A1 (es) |
| PL (1) | PL3768684T3 (es) |
| RS (1) | RS64156B1 (es) |
| SG (1) | SG11202007608UA (es) |
| SI (1) | SI3768684T1 (es) |
| TW (1) | TWI818967B (es) |
| WO (1) | WO2019180185A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| LT3837263T (lt) | 2018-08-13 | 2024-09-25 | F. Hoffmann-La Roche Ag | Nauji heterocikliniai junginiai kaip monoacilglicerolio lipazės inhibitoriai |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| EP4028403B1 (en) * | 2019-09-12 | 2023-11-22 | F. Hoffmann-La Roche AG | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| CN114401969A (zh) * | 2019-09-23 | 2022-04-26 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
| CN114514233A (zh) * | 2019-09-24 | 2022-05-17 | 豪夫迈·罗氏有限公司 | 用于单酰基甘油脂肪酶(magl)的荧光探针 |
| CR20220118A (es) * | 2019-09-24 | 2022-04-20 | Hoffmann La Roche | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) |
| EP4034541A1 (en) * | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | Heterocyclic compounds |
| IL299664A (en) | 2020-09-03 | 2023-03-01 | Hoffmann La Roche | Heterocyclic compounds |
| EP4416131A4 (en) * | 2021-10-15 | 2025-07-30 | Genetolead Inc | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4457213A1 (en) | 2021-12-29 | 2024-11-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| JP2025525350A (ja) * | 2022-06-24 | 2025-08-05 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤としての新規複素環－カルボニル－環式化合物 |
| TW202415651A (zh) | 2022-07-29 | 2024-04-16 | 日商住友製藥股份有限公司 | 含氮飽和雜環衍生物 |
| WO2024061853A1 (en) * | 2022-09-20 | 2024-03-28 | F. Hoffmann-La Roche Ag | Fluorescent probes for magl |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| JP2008543940A (ja) | 2005-06-20 | 2008-12-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用な、炭素結合した置換ピペリジンおよびその誘導体 |
| EP1984351A1 (en) | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| CA2836311A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| EP3698782B1 (en) | 2012-01-06 | 2024-05-15 | H. Lundbeck A/S | Carbamate compounds for use in therapy |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| WO2016180536A1 (en) | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
| BR112017024678A2 (pt) | 2015-05-21 | 2018-07-31 | Glaxosmithkline Intellectual Property Development Limited | derivados de benzoimidazol como inibidores de pad4 |
| ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
| CN105198903B (zh) * | 2015-11-09 | 2016-08-24 | 代先慧 | 一种治疗急性上呼吸道感染的药物组合物 |
| US10610520B2 (en) | 2016-03-31 | 2020-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2019
- 2019-03-22 HR HRP20230388TT patent/HRP20230388T1/hr unknown
- 2019-03-22 PE PE2020001119A patent/PE20201185A1/es unknown
- 2019-03-22 CN CN201980018255.1A patent/CN111936503B/zh active Active
- 2019-03-22 CA CA3089443A patent/CA3089443A1/en active Pending
- 2019-03-22 MX MX2020008894A patent/MX2020008894A/es unknown
- 2019-03-22 CR CR20200416A patent/CR20200416A/es unknown
- 2019-03-22 EP EP19711920.9A patent/EP3768684B1/en active Active
- 2019-03-22 ES ES19711920T patent/ES2942319T3/es active Active
- 2019-03-22 DK DK19711920.9T patent/DK3768684T3/da active
- 2019-03-22 SG SG11202007608UA patent/SG11202007608UA/en unknown
- 2019-03-22 LT LTEPPCT/EP2019/057174T patent/LT3768684T/lt unknown
- 2019-03-22 WO PCT/EP2019/057174 patent/WO2019180185A1/en not_active Ceased
- 2019-03-22 KR KR1020207029587A patent/KR20200136425A/ko active Pending
- 2019-03-22 JP JP2020548747A patent/JP7308220B2/ja active Active
- 2019-03-22 FI FIEP19711920.9T patent/FI3768684T3/fi active
- 2019-03-22 BR BR112020014992-6A patent/BR112020014992A2/pt not_active Application Discontinuation
- 2019-03-22 SI SI201930519T patent/SI3768684T1/sl unknown
- 2019-03-22 HU HUE19711920A patent/HUE061584T2/hu unknown
- 2019-03-22 AU AU2019238381A patent/AU2019238381B2/en not_active Ceased
- 2019-03-22 RS RS20230303A patent/RS64156B1/sr unknown
- 2019-03-22 TW TW108110005A patent/TWI818967B/zh not_active IP Right Cessation
- 2019-03-22 PL PL19711920.9T patent/PL3768684T3/pl unknown
-
2020
- 2020-07-13 IL IL276031A patent/IL276031B2/en unknown
- 2020-07-31 CO CONC2020/0009567A patent/CO2020009567A2/es unknown
- 2020-09-08 PH PH12020500661A patent/PH12020500661A1/en unknown
- 2020-09-18 US US17/025,155 patent/US20210107920A1/en not_active Abandoned
- 2020-09-21 CL CL2020002423A patent/CL2020002423A1/es unknown
-
2022
- 2022-08-09 US US17/818,459 patent/US20230117324A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
| PE20221628A1 (es) | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20180501A1 (es) | Lactamas biciclicas y metodos de uso de las mismas | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| MX390348B (es) | Compuestos de benzimidazol como inhibidores de c-kit | |
| CL2008001303A1 (es) | Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer. | |
| PE20120418A1 (es) | DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP) | |
| PE20160875A1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| MX338772B (es) | Fungicidas de benceno sustituido. | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| PE20210131A1 (es) | COMPUESTOS TETRAHIDRO-1H-PIRAZINO[2,1-a]ISOINDOLILQUINOLINA PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES | |
| CL2009001044A1 (es) | Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades. | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| MX2007007103A (es) | Derivados espiro como inhibidores de lipoxigenasa. | |
| PA8614301A1 (es) | Derivados de tropano | |
| ECSP066504A (es) | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina | |
| MX2017016908A (es) | Inhibidores de nadph oxidasa 4. | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CR20160236A (es) | Derivados de purina 2,6- sustituidos y su uso en el tratamiento de desordenes proliferativos |